Best article from the June 2020 special issue on Nanomedicines

New Content ItemRead the best article from the June 2020 issue!

Summary: Bevacizumab is a monoclonal antibody that specifically inactivates VEGF-A, resulting in a decrease of the development of tumor blood vessels and its growth. Currently, it is employed in the treatment of different types of tumors, particularly colorectal cancer. As for other biologicals, the benefits of bevacizumab are limited by a low capability to penetrate into the tumors that, in addition, may increase the risk of acquiring resistance. In this work, the effect of the nanoencapsulation of bevacizumab (in human serum albumin nanoparticles) was evaluated on a xenograft model of human colorectal cancer.   

The resulting nanoparticles demonstrated to be more effective in decreasing the glycolysis and metabolic tumor volume than the conventional treatment. This improvement was associated with a significantly higher accumulation of the monoclonal antibody in the tumor tissues when nanoencapsulated in human serum albumin nanoparticles.

This article was selected as the best article of the Nanomedicines Special Issue by the CRS Nanomedicine and Nanoscale Delivery Focus Group.